Hunting new deals, Eli Lilly buddies up on diabetes R&D with $55M pact
New Eli Lilly CEO David Ricks has another deal to report.
Just a few months after completing a pact to acquire CoLucid’s migraine drug in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
